A phase II study of every other day high-dose ifosfamide in pediatric brain tumors
β Scribed by Richard L. Heideman; Edwin C. Douglass; James A. Langston; Jeffrey P. Krischer; Peter C. Burger; Edward H. Kovnar; Larry E. Kun; Henry S. Friedman; Richard Kadota
- Publisher
- Springer US
- Year
- 1995
- Tongue
- English
- Weight
- 683 KB
- Volume
- 25
- Category
- Article
- ISSN
- 0167-594X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract Fortyβtwo evaluable pediatric patients with a variety of recurrent primary brain tumors participated in a phase II ifosfamide trial. Their mean age was 10 years. All patients were treated with ifosfamide, 3 g/m^2^/day for 2 days every 2 weeks. Response was assessed on clinical and radio
Background. The prognosis for children with recurrent or resistant malignant solid tumors remains dismal. More effective rescue therapy is needed for these children. Methods. Between August 1987 and November 1990, 311 children with recurrent or resistant malignant solid tumors were treated by inves
## Background: Chemotherapy is used as an alternative to irradiation or to minimize the irradiation exposure among infants with medulloblastoma or other cns embryonal tumors. adjuvant chemotherapy is commonly used in older children with high-risk medulloblastoma to improve survival or to allow a re